The generation of immune memory is critical for long‐lasting anti‐tumor immune responses and the prevention of tumor recurrence.[53, 54] LLI (+) and LLI (+) combined with anti‐PD‐1 antibody treatments showed much higher percentages of TEMs (CD3+CD8+CD44+CD62L−), and LLI (+) combined with anti‐PD‐1 antibody treatment further increased TEM levels compared with the LLI (+) treatment (Figure 8D,I). This evidence concerns the gene CD8A and neoplasm.